Biomednewsbreaks Heartbeam Inc. (NASDAQ: BEAT) Announces Conference Call, Webcast To Discuss Q2 Results

(MENAFN- Investor Brand Network) HeartBeam(NASDAQ: BEAT),
a medical technology company focused on transforming cardiac care through the power of personalized insights, has scheduled a conference call and webcast to discuss its second-quarter 2024 results. According to the announcement, the call is slated to begin at 4:30 p.m. ET on Aug. 14, 2024. HeartBeam executives, including Branislav Vajdic, CEO and founder; Robert Eno, president; and Ravi Malhotra, senior director and corporate controller, will host the call. During the call, the company leaders will discuss second-quarter results, provide regulatory updates, and review ongoing initiatives and anticipated 2024 milestones; the call will also include a question-and-answer period. The company noted that the call will include a presentation, which will also be available on the company website. Those interested in accessing the call can dial 1-844-826-3035 (U.S.) or 1-412-317-5195 (international), and then use conference code 10191273. In addition, a replay of the call will be available. Those wishing to access the replay can dial 1-844-512-2921 (U.S.) or 1-412-317-6671 (international) and then enter the replay pin number 10191273.

To view the presentation, visit

To view the webcast, visit

To view the full press release, visit

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care through the power of personalized insights. The company's proprietary vectorelectrocardiography (“VECG”) technology collects 3D signals of the heart's electrical activity and converts those signals into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card-sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care, all outside of a medical facility, thus redefining how cardiac health is managed. For more information, visit
.

NOTE TO INVESTORS:
The latest news and updates relating to BEAT are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
...

BioMedWire is powered by
IBN

MENAFN01082024000224011066ID1108507295